कृपया अन्य खोज का प्रयास करें
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Colin Louis Masters | 76 | 1999 | Member of Research & Development Advisory Board |
Geoffrey Paul Kempler | 68 | 1997 | Co-Founder & Non-Executive Chairman |
Ira Shoulson | 77 | 2014 | Chairman of Research & Development Advisory Board |
Rudolph Emile Tanzi | 64 | 2007 | Chief Scientific Advisor and Member of Research & Development Advisory Board |
Lawrence B. Gozlan | 44 | 2011 | Non-Executive Director |
Peter Ashley Marks | 67 | 2005 | Non-Executive Independent Director |
Brian Derek Meltzer | 69 | 1999 | Non-Executive Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है